Comments
Lilly projects sharp drop in 2012 profit
05.01.2012. | (Reuters) - Eli Lilly & Co forecast a sharp plunge in profits for 2012, the first full year its top-selling Zyprexa schizophrenia treatment faces generic competition, and its shares fell as much as 3.6 percent....
